8 July 2021 - House Democrats on Thursday released a report that found that the 14 leading drug companies paid out more in stock buybacks and dividends from 2016 to 2020 than they spent on research and development.
The report from the House Oversight and Reform Committee finds that the 14 companies spent $577 billion from 2016 to 2020 on stock buybacks and dividends, $56 billion more than the $521 billion they spent on research and development over the same time period.